Skip to main content
OpenTrials

Clinical trial condition

FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma

Explore clinical trials studying FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma. Study availability and eligibility vary by location and protocol.

8 public trials 1 recruiting study
Refine in advanced search Browse all conditions

FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma trial results

Recruiting

Outcomes of Low-Risk Endometrial Cancer With Isolated Tumor Cells in the Sentinel Lymph Nodes: A Prospective, Multicenter, Single-Arm Observational Study

NCT06689956

Conditions
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Stage IA1 Endometrial Cancer FIGO 2023, +1 more
Locations
  • Mayo Clinic in Rochester Rochester, Minnesota, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
  • Houston Methodist Hospital Houston, Texas, United States
  • Medical University of Vienna Vienna, Austria
View all 20 locations
View Trial Details
Completed

Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer

NCT03300557

Conditions
Atypical Hyperplasia, Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, Endometrial Carcinoma, +15 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • University of Minnesota/Masonic Cancer Center Minneapolis, Minnesota, United States
  • University of Wisconsin Carbone Cancer Center - University Hospital Madison, Wisconsin, United States
View Trial Details
Completed

Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer

NCT03018249

Conditions
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 3 Endometrial Endometrioid Adenocarcinoma
Locations
  • CHI Saint Vincent Cancer Center Hot Springs Hot Springs, Arkansas, United States
  • John Muir Medical Center-Concord Campus Concord, California, United States
  • John Muir Medical Center-Walnut Creek Walnut Creek, California, United States
  • Rocky Mountain Cancer Centers-Aurora Aurora, Colorado, United States
View all 234 locations
View Trial Details
Active, Not Recruiting

Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

NCT05538897

Conditions
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Metastatic Endometrial Endometrioid Adenocarcinoma, +1 more
Locations
  • Banner University Medical Center - Tucson Tucson, Arizona, United States
  • University of Arizona Cancer Center-North Campus Tucson, Arizona, United States
  • Highlands Oncology Group - Fayetteville Fayetteville, Arkansas, United States
  • Highlands Oncology Group - Rogers Rogers, Arkansas, United States
View all 152 locations
View Trial Details
Active, Not Recruiting

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

NCT04092270

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +43 more
Locations
  • UCHealth University of Colorado Hospital Aurora, Colorado, United States
  • Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Memorial Sloan Kettering Monmouth Middletown, New Jersey, United States
View Trial Details
Active, Not Recruiting

Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer

NCT02397083

Conditions
Atypical Endometrial Hyperplasia, Endometrial Hyperplasia, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, +7 more
Locations
  • North Colorado Medical Center Greeley, Colorado, United States
  • McKee Medical Center Loveland, Colorado, United States
  • Queen's Medical Center Honolulu, Hawaii, United States
  • Covenant HealthCare Mackinaw Saginaw, Michigan, United States
View all 18 locations
View Trial Details

Related conditions